Connor Clark & Lunn Investment Management Ltd. bought a new position in CONMED Corporation (NYSE:CNMD - Free Report) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 21,891 shares of the company's stock, valued at approximately $716,000. Connor Clark & Lunn Investment Management Ltd. owned about 0.07% of CONMED as of its most recent filing with the Securities and Exchange Commission.
Other large investors have also modified their holdings of the company. BlackRock Inc. acquired a new position in CONMED in the second quarter worth about $157,783,000. Vanguard Group Inc. grew its position in shares of CONMED by 2.0% in the 4th quarter. Vanguard Group Inc. now owns 3,684,439 shares of the company's stock worth $149,588,000 after acquiring an additional 73,533 shares in the last quarter. Dimensional Fund Advisors LP grew its position in shares of CONMED by 6.1% in the 1st quarter. Dimensional Fund Advisors LP now owns 1,392,920 shares of the company's stock worth $49,250,000 after acquiring an additional 80,116 shares in the last quarter. Wasatch Advisors LP bought a new stake in shares of CONMED in the 3rd quarter valued at approximately $47,026,000. Finally, Cooke & Bieler LP increased its holdings in shares of CONMED by 23.2% in the 4th quarter. Cooke & Bieler LP now owns 867,817 shares of the company's stock valued at $35,233,000 after acquiring an additional 163,494 shares during the last quarter.
CONMED Trading Down 0.5%
Shares of CNMD stock opened at $49.73 on Tuesday. CONMED Corporation has a fifty-two week low of $31.44 and a fifty-two week high of $56.63. The stock has a market capitalization of $1.49 billion, a P/E ratio of 26.88, a P/E/G ratio of 2.28 and a beta of 0.88. The stock has a 50-day simple moving average of $43.81 and a 200 day simple moving average of $39.86. The company has a quick ratio of 0.69, a current ratio of 1.48 and a debt-to-equity ratio of 0.63.
CONMED (NYSE:CNMD - Get Free Report) last issued its quarterly earnings results on Wednesday, July 29th. The company reported $1.38 earnings per share for the quarter, topping analysts' consensus estimates of $1.11 by $0.27. The firm had revenue of $343.49 million for the quarter, compared to analysts' expectations of $337.60 million. CONMED had a return on equity of 14.31% and a net margin of 4.12%.CONMED's revenue was up .3% on a year-over-year basis. During the same quarter last year, the business posted $1.15 EPS. CONMED has set its FY 2026 guidance at 4.480-4.600 EPS. On average, sell-side analysts expect that CONMED Corporation will post 4.54 earnings per share for the current fiscal year.
Analyst Ratings Changes
Several equities analysts recently issued reports on the company. Wall Street Zen upgraded CONMED from a "hold" rating to a "buy" rating in a research note on Monday, July 20th. Needham & Company LLC reiterated a "hold" rating on shares of CONMED in a research note on Monday, July 13th. Zacks Research raised shares of CONMED from a "strong sell" rating to a "hold" rating in a report on Tuesday, August 11th. Wells Fargo & Company raised their price target on shares of CONMED from $39.00 to $46.00 and gave the stock an "equal weight" rating in a research report on Thursday, July 30th. Finally, Weiss Ratings raised shares of CONMED from a "sell (d)" rating to a "sell (d+)" rating in a report on Wednesday, August 5th. Six research analysts have rated the stock with a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, CONMED has a consensus rating of "Reduce" and a consensus target price of $41.40.
Get Our Latest Analysis on CONMED
CONMED Profile
(
Free Report)
CONMED Corporation NYSE: CNMD is a global medical technology company headquartered in Utica, New York. Founded in 1970, CONMED develops, manufactures and markets a broad portfolio of surgical devices and accessories for minimally invasive procedures. The company's product line supports surgeons and healthcare providers in specialties including orthopedics, general surgery, gastroenterology and gynecology.
CONMED operates two principal segments: Orthopedics, and Visualization & Energy.
See Also
Want to see what other hedge funds are holding CNMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CONMED Corporation (NYSE:CNMD - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider CONMED, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CONMED wasn't on the list.
While CONMED currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
